AU2021385745C1 - Aminoheteroaryl kinase inhibitors - Google Patents

Aminoheteroaryl kinase inhibitors Download PDF

Info

Publication number
AU2021385745C1
AU2021385745C1 AU2021385745A AU2021385745A AU2021385745C1 AU 2021385745 C1 AU2021385745 C1 AU 2021385745C1 AU 2021385745 A AU2021385745 A AU 2021385745A AU 2021385745 A AU2021385745 A AU 2021385745A AU 2021385745 C1 AU2021385745 C1 AU 2021385745C1
Authority
AU
Australia
Prior art keywords
optionally substituted
formula
compound
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021385745A
Other languages
English (en)
Other versions
AU2021385745B2 (en
AU2021385745A9 (en
AU2021385745A1 (en
Inventor
Dai Cheng
Qiang Ding
Zhixiang HE
Zeqiang XIE
Xiaohang YIN
Xiaobo Zhou
Yang Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allorion Therapeutics Inc
Original Assignee
Allorion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allorion Therapeutics Inc filed Critical Allorion Therapeutics Inc
Publication of AU2021385745A1 publication Critical patent/AU2021385745A1/en
Assigned to Allorion Therapeutics Inc reassignment Allorion Therapeutics Inc Request for Assignment Assignors: ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD.
Publication of AU2021385745B2 publication Critical patent/AU2021385745B2/en
Priority to AU2025200001A priority Critical patent/AU2025200001A1/en
Application granted granted Critical
Publication of AU2021385745C1 publication Critical patent/AU2021385745C1/en
Publication of AU2021385745A9 publication Critical patent/AU2021385745A9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of El Displays (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021385745A 2020-11-27 2021-11-26 Aminoheteroaryl kinase inhibitors Active AU2021385745C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200001A AU2025200001A1 (en) 2020-11-27 2025-01-02 Aminoheteroaryl kinase inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020132454 2020-11-27
CNPCT/CN2020/132454 2020-11-27
CNPCT/CN2021/081236 2021-03-17
CN2021081236 2021-03-17
PCT/CN2021/133429 WO2022111621A1 (en) 2020-11-27 2021-11-26 Aminoheteroaryl kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200001A Division AU2025200001A1 (en) 2020-11-27 2025-01-02 Aminoheteroaryl kinase inhibitors

Publications (4)

Publication Number Publication Date
AU2021385745A1 AU2021385745A1 (en) 2023-06-15
AU2021385745B2 AU2021385745B2 (en) 2024-10-03
AU2021385745C1 true AU2021385745C1 (en) 2025-02-20
AU2021385745A9 AU2021385745A9 (en) 2025-03-27

Family

ID=81753779

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2021385745A Active AU2021385745C1 (en) 2020-11-27 2021-11-26 Aminoheteroaryl kinase inhibitors
AU2022397678A Pending AU2022397678A1 (en) 2020-11-27 2022-11-23 Aminoheteroaryl kinase inhibitors
AU2025200001A Pending AU2025200001A1 (en) 2020-11-27 2025-01-02 Aminoheteroaryl kinase inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022397678A Pending AU2022397678A1 (en) 2020-11-27 2022-11-23 Aminoheteroaryl kinase inhibitors
AU2025200001A Pending AU2025200001A1 (en) 2020-11-27 2025-01-02 Aminoheteroaryl kinase inhibitors

Country Status (10)

Country Link
US (2) US20240166635A1 (https=)
EP (2) EP4251613A4 (https=)
JP (2) JP2024506116A (https=)
KR (1) KR20230127228A (https=)
CN (2) CN116528869B (https=)
AU (3) AU2021385745C1 (https=)
CA (2) CA3202990A1 (https=)
IL (1) IL303237A (https=)
MX (1) MX2024006300A (https=)
WO (2) WO2022111621A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS
CA3207392A1 (en) * 2021-02-05 2022-08-11 Xiaoxia Yan Cdk inhibitor
EP4532473A1 (en) * 2022-05-27 2025-04-09 Allorion Therapeutics Inc. Aminoheteroaryl kinase inhibitors
WO2025006400A1 (en) * 2023-06-25 2025-01-02 Allorion Therapeutics Inc Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
EP4725942A1 (en) * 2024-10-09 2026-04-15 Sibylla Biotech S.p.A. Compounds active on cyclin d1 pathway and their use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096887A1 (en) * 2001-05-30 2002-12-05 Astrazeneca Ab 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
WO2002096888A1 (de) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
WO2006087230A1 (de) * 2005-02-17 2006-08-24 Schering Aktiengesellschaft Verwendung von cdk ii inhibitoren zur fertilitätskontrolle
WO2010046034A1 (de) * 2008-10-21 2010-04-29 Bayer Schering Pharma Aktiengesellschaft Sulfonsubsituierte anilino-pyrimidinderivate als cdk-inhibitoren, deren herstellung und verwendung als arzneimittel
WO2010058030A1 (en) * 2008-11-24 2010-05-27 Boehringer Ingelheim International Gmbh New compounds
NZ629830A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
WO2021170076A1 (en) * 2020-02-28 2021-09-02 Fochon Pharmaceuticals, Ltd. Compounds as cdk2/4/6 inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
BR0116452A (pt) * 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
IL161663A0 (en) * 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3beta INHIBITORS
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1483260A1 (de) * 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
AU2006244195B2 (en) * 2005-05-05 2012-03-15 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
AU2007338792B2 (en) * 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
CN101679440A (zh) * 2007-04-02 2010-03-24 帕劳制药股份有限公司 作为jak3抑制剂的吡咯并嘧啶衍生物
WO2008128231A1 (en) * 2007-04-16 2008-10-23 Hutchison Medipharma Enterprises Limited Pyrimidine derivatives
CN101678215B (zh) * 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
WO2009022171A1 (en) * 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
US9145402B2 (en) * 2011-11-29 2015-09-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
CN110386901B (zh) * 2018-04-23 2022-11-25 上海医药工业研究院 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用
WO2019213340A1 (en) * 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
WO2020205560A1 (en) * 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US20230411615A1 (en) * 2020-11-04 2023-12-21 Umicore A positive electrode active material for rechargeable batteries
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS
CA3207392A1 (en) * 2021-02-05 2022-08-11 Xiaoxia Yan Cdk inhibitor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096888A1 (de) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
WO2002096887A1 (en) * 2001-05-30 2002-12-05 Astrazeneca Ab 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
WO2006087230A1 (de) * 2005-02-17 2006-08-24 Schering Aktiengesellschaft Verwendung von cdk ii inhibitoren zur fertilitätskontrolle
WO2010046034A1 (de) * 2008-10-21 2010-04-29 Bayer Schering Pharma Aktiengesellschaft Sulfonsubsituierte anilino-pyrimidinderivate als cdk-inhibitoren, deren herstellung und verwendung als arzneimittel
WO2010058030A1 (en) * 2008-11-24 2010-05-27 Boehringer Ingelheim International Gmbh New compounds
NZ629830A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
WO2021170076A1 (en) * 2020-02-28 2021-09-02 Fochon Pharmaceuticals, Ltd. Compounds as cdk2/4/6 inhibitors

Also Published As

Publication number Publication date
AU2021385745B2 (en) 2024-10-03
CN116528869A (zh) 2023-08-01
US20250002480A1 (en) 2025-01-02
EP4436959A1 (en) 2024-10-02
EP4436959A4 (en) 2026-02-11
JP2024506116A (ja) 2024-02-09
MX2024006300A (es) 2024-07-24
CN118475562A (zh) 2024-08-09
AU2021385745A9 (en) 2025-03-27
EP4251613A4 (en) 2024-11-20
CN116528869B (zh) 2026-04-14
AU2025200001A1 (en) 2025-01-23
US20240166635A1 (en) 2024-05-23
CA3238970A1 (en) 2023-06-01
IL303237A (en) 2023-07-01
EP4251613A1 (en) 2023-10-04
JP2024541533A (ja) 2024-11-08
WO2022111621A1 (en) 2022-06-02
KR20230127228A (ko) 2023-08-31
WO2023093769A1 (en) 2023-06-01
AU2022397678A1 (en) 2024-05-30
CA3202990A1 (en) 2022-06-02
AU2021385745A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
AU2021385745C1 (en) Aminoheteroaryl kinase inhibitors
ES2619125T3 (es) Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa
US20250154148A1 (en) Kras inhibitors
EP2991977B1 (en) C-linked heterocycloalkyl substituted pyrimidines and their uses
CN115996929B (zh) 腺苷A2a受体的拮抗剂
CA2931034C (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
EP3768660A1 (en) Modulators of eukaryotic initiation factor 2
AU2014261894A1 (en) Biheteroaryl compounds and uses thereof
WO2020086857A1 (en) Wdr5 inhibitors and modulators
EP3546458B1 (en) ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer
KR101947289B1 (ko) 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제
CA2957048A1 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US12435063B2 (en) Nitrogen containing heterocycles as CDK12 inhibitors
CN106608879A (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
KR20180095054A (ko) 피롤로피리미딘 화합물에 의한 항종양 효과 증강제
JP2016511247A (ja) ビシクロ２，３−ベンゾジアゼピン類及びスピロ環式置換２，３−ベンゾジアゼピン類
US20250320185A1 (en) Aminoheteroaryl kinase inhibitors
EP4562016A2 (en) Cdk2 inhibitors and methods of using the same
WO2022253309A1 (zh) 取代的杂环化合物及其应用
EP4219500A1 (en) Condensed heterocyclic compound
EP3733206A1 (en) Anticancer agent
JP2023545196A (ja) 三複素環誘導体、その医薬組成物及び使用
OA20759A (en) Benzimidazole derivatives.
HK40043646A (en) Heterocyclic compound
HK40043646B (en) Heterocyclic compound

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ALLORION THERAPEUTICS INC

Free format text: FORMER APPLICANT(S): ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 OCT 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 18 OCT 2024

FGA Letters patent sealed or granted (standard patent)
SREP Specification republished